Back to Search
MICHAEL DEININGER, MD
MD
Hematology (Internal Medicine) Physician
NPI: 1932115524Individual
Specialties, Licenses & Credentials
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
76729(WI)
Research & Publications (20)
Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.
PMID 19340004·Leukemia·2009
8-other
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia.
PMID 18615102·Leukemia·2009
8-other
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
PMID 18615105·Leukemia·2009
8-other
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
PMID 19075190·Blood·2009
7-preclinical
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
PMID 19568437·PLoS One·2009
8-other
Minimally invasive dorsal percutaneous spondylodesis for the treatment of adult pyogenic spondylodiscitis.
PMID 19468676·Acta Neurochir (Wien)·2009
8-other
Gravitational valves in supine patients with ventriculo-peritoneal shunts.
PMID 19337679·Acta Neurochir (Wien)·2009
5-case
RNAi screen for rapid therapeutic target identification in leukemia patients.
PMID 19433805·Proc Natl Acad Sci U S A·2009
8-other
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
PMID 19625707·Blood·2009
8-other
Milestones and monitoring in patients with CML treated with imatinib.
PMID 19074120·Hematology Am Soc Hematol Educ Program·2008
6-review
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
PMID 18541900·J Clin Oncol·2008
3-trial
Chronic myeloid leukemia: an historical perspective.
PMID 19074119·Hematology Am Soc Hematol Educ Program·2008
8-other
New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?
PMID 19254881·Clin Lymphoma Myeloma·2008
6-review
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
PMID 18559973·Blood·2008
7-preclinical
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
PMID 18548107·Leukemia·2008
7-preclinical
Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia.
PMID 18577744·J Natl Cancer Inst·2008
8-other
Bedside catheter evacuation of predominantly isolated traumatic supratentorial hemorrhage.
PMID 19001993·J Trauma·2008
8-other
Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR.
PMID 18615107·Leukemia·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9200 W WISCONSIN AVE
MILWAUKEE, WI 53226 - Phone
- (414) 805-0505
Quick Facts
- NPI
- 1932115524
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile